Literature DB >> 21555893

Renal Association Clinical Practice Guideline in mineral and bone disorders in CKD.

Simon Steddon1, Edward Sharples.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21555893     DOI: 10.1159/000328066

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


× No keyword cloud information.
  7 in total

1.  Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.

Authors:  Melissa Soohoo; Mingliang Feng; Yoshitsugu Obi; Elani Streja; Connie M Rhee; Wei Ling Lau; Jialin Wang; Vanessa A Ravel; Steven Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2016-03-08       Impact factor: 3.754

Review 2.  Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease.

Authors:  Catharine M Sturgeon; Stuart M Sprague; Wendy Metcalfe
Journal:  Nephrol Dial Transplant       Date:  2011-11       Impact factor: 5.992

Review 3.  Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations.

Authors:  Eunah Hwang; Bum Soon Choi; Kook-Hwan Oh; Young Joo Kwon; Gheun-Ho Kim
Journal:  Kidney Res Clin Pract       Date:  2015-02-24

4.  Stabilization of serum alkaline phosphatase in hemodialysis patients by implementation of local chronic kidney disease-mineral bone disorder management strategy: A quality improvement study.

Authors:  Kyubok Jin; Tae Hyun Ban; Ji Yong Jung; Ae Jin Kim; Yaerim Kim; So-Young Lee; Dong Ho Yang; Bum Soon Choi; Kook-Hwan Oh; Jieun Kim; Young Joo Kwon; Jong Wook Choi; Gheun-Ho Kim
Journal:  Kidney Res Clin Pract       Date:  2018-06-30

5.  Hip fracture incidence and mortality in chronic kidney disease: the GLOMMS-II record linkage cohort study.

Authors:  Lynn Robertson; Corrinda Black; Nick Fluck; Sharon Gordon; Rosemary Hollick; Huong Nguyen; Gordon Prescott; Angharad Marks
Journal:  BMJ Open       Date:  2018-04-12       Impact factor: 2.692

Review 6.  Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence.

Authors:  M Jesús Lloret; César Ruiz-García; Iara Dasilva; Mónica Furlano; Yaima Barreiro; José Ballarín; Jordi Bover
Journal:  Patient Prefer Adherence       Date:  2013-11-06       Impact factor: 2.711

Review 7.  Moxibustion as an Adjuvant Therapy for Chronic Kidney Disease: A Systematic Review and Meta-Analysis of 23 Randomized Controlled Trials.

Authors:  Xu Zhou; Qingni Wu; Yanping Wang; Qing Ren; Weifeng Zhu; Ziqian Yao; Jianrong Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-28       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.